MX2016016071A - Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos. - Google Patents
Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos.Info
- Publication number
- MX2016016071A MX2016016071A MX2016016071A MX2016016071A MX2016016071A MX 2016016071 A MX2016016071 A MX 2016016071A MX 2016016071 A MX2016016071 A MX 2016016071A MX 2016016071 A MX2016016071 A MX 2016016071A MX 2016016071 A MX2016016071 A MX 2016016071A
- Authority
- MX
- Mexico
- Prior art keywords
- nicotinamide riboside
- branched
- straight chain
- pharmaceutical compositions
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
En la presente memoria se proporcionan análogos de éster y carbonato de ribósido de nicotinamida y de hidruro de ribósido de nicotinamida estereoisoméricamente puros, y composiciones farmacéuticas y usos de los mismos; los análogos de éster y carbonato de ribósido de nicotinamida y de hidruro de ribósido de nicotinamida estereoisoméricamente puros pueden usarse para tratar una enfermedad o trastorno que podría beneficiarse de los niveles de NAD aumentados, incluyendo una enfermedad o trastorno mitocondrial, resistencia a la insulina, un síndrome metabólico, diabetes, obesidad, para aumentar la sensibilidad a la insulina en un sujeto, o para tratar o prevenir una afección cutánea; los compuestos tienen fórmulas generales (I) o (II) en donbde R1 es -C(=0)-X-alquilo (C2-C18 de cadena lineal o ramificada) o -C(.=0)-X-alquenilo (C2-C18 de cadena lineal o ramificada); cada R2 se selecciona independientemente entre hidrógeno, y un -C(0)-X-alquilo (C2-C18 de cadena lineal o ramificada) o un -C(0)-X-alquenilo (C2-C18 de cadena lineal o ramificada); y X es un enlace covalente u O. (FORMULAS).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462008707P | 2014-06-06 | 2014-06-06 | |
PCT/IB2015/054281 WO2015186114A1 (en) | 2014-06-06 | 2015-06-05 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016016071A true MX2016016071A (es) | 2017-07-11 |
Family
ID=53398163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016016071A MX2016016071A (es) | 2014-06-06 | 2015-06-05 | Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US10485814B2 (es) |
EP (1) | EP3152220A1 (es) |
JP (1) | JP6559713B2 (es) |
KR (1) | KR20170008320A (es) |
CN (1) | CN106715455A (es) |
AU (1) | AU2015270090A1 (es) |
BR (1) | BR112016028672A2 (es) |
CA (1) | CA2951287A1 (es) |
MX (1) | MX2016016071A (es) |
RU (1) | RU2016149767A (es) |
WO (1) | WO2015186114A1 (es) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106715454B (zh) | 2014-07-24 | 2020-06-16 | 格雷斯公司 | 烟酰胺核苷的结晶形式 |
MX2017011851A (es) * | 2015-03-16 | 2018-04-11 | Chromadex Inc | Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. |
US20160317418A1 (en) * | 2015-05-01 | 2016-11-03 | The Procter & Gamble Company | Method of improving the appearance of skin and compositions therefor |
US11426398B2 (en) | 2015-06-10 | 2022-08-30 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
US11013678B2 (en) | 2015-06-29 | 2021-05-25 | The Procter & Gamble Company | Multi-component skin care product |
US10392414B2 (en) | 2015-07-15 | 2019-08-27 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
EP3331894B1 (en) | 2015-08-05 | 2021-02-17 | Metro International Biotech, LLC | Nicotinamide mononucleotide derivatives and their uses |
ES2812456T3 (es) * | 2015-12-21 | 2021-03-17 | Showa Denko Kk | Derivado de mononucleótido de nicotinamida y sal del mismo, método para producir el mismo, agente tópico, cosmético y aditivo alimentario |
EP3236928B1 (en) | 2016-01-11 | 2020-12-09 | The Procter and Gamble Company | Method of treating a skin condition and compositions therefor |
EP3429354A4 (en) | 2016-03-16 | 2020-03-25 | Chromadex Inc. | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF AND METHOD FOR THE PRODUCTION THEREOF |
NZ747693A (en) | 2016-04-20 | 2023-07-28 | Chromadex Inc | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors |
EP4252775A3 (en) | 2016-07-15 | 2023-12-20 | H2 Water Technologies Ltd | Composition for producing hydrogen rich water |
GB2553001A (en) * | 2016-08-19 | 2018-02-21 | The Queen's Univ Of Belfast | Lactone intermediates of nicotinamide riboside and nicotinate riboside |
US9975915B1 (en) | 2016-11-11 | 2018-05-22 | The Queen's University Of Belfast | Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof |
US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
CA3044814A1 (en) | 2016-11-29 | 2018-06-07 | Charles M. Brenner | Use of nad precursors for improving maternal health and/or offspring health |
US20200121704A1 (en) * | 2017-01-13 | 2020-04-23 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating hypertension and arterial stiffness |
PT3606929T (pt) * | 2017-04-05 | 2021-09-02 | Univ Cornell | Nucleótidos de éster de beta-nicotinato e processos de preparação dos mesmos |
WO2018200357A1 (en) * | 2017-04-26 | 2018-11-01 | Elysium Health, Inc. | Methods and compositions of improving fertility |
US20200179441A1 (en) * | 2017-04-27 | 2020-06-11 | H2 Water Technologies Ltd. | Synergistic compositions for increasing mitochondrial function and energy |
US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
JP6997222B2 (ja) | 2017-06-23 | 2022-01-17 | ザ プロクター アンド ギャンブル カンパニー | 皮膚の外観を改善するための組成物及び方法 |
CN111601814A (zh) * | 2017-10-19 | 2020-08-28 | 益力舒健康公司 | Tdp-43相关疾病的预防和治疗 |
US20200261483A1 (en) * | 2017-10-30 | 2020-08-20 | Elysium Health, Inc. | Methods and compositions for treating cystic fibrosis |
US20210177875A1 (en) * | 2017-12-01 | 2021-06-17 | Elysium Health, Inc. | Methods and compositions for treating childhood or teen obesity |
EP3794011A1 (en) * | 2018-05-15 | 2021-03-24 | Jumpstart Fertility Pty Ltd | Amino acid salts of nicotinic acid mononucleotide and nicotinamide mononucleotide as anti-ageing agents |
CN113490675A (zh) * | 2018-05-22 | 2021-10-08 | 江普斯塔特生育有限公司 | 作为抗衰老剂的烟酸核苷的氨基酸盐 |
WO2020010036A1 (en) | 2018-07-03 | 2020-01-09 | The Procter & Gamble Company | Method of treating a skin condition |
CN108774278A (zh) * | 2018-09-10 | 2018-11-09 | 张洪喜 | 一种制备尼克酰胺核苷盐的方法 |
WO2020081361A1 (en) * | 2018-10-17 | 2020-04-23 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
EP3897666A2 (en) | 2018-12-17 | 2021-10-27 | Mitopower LLC | Nicotinyl riboside compounds and their uses |
CN109674808A (zh) * | 2019-01-30 | 2019-04-26 | 四川大学 | β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途 |
MX2021010043A (es) * | 2019-02-21 | 2022-07-19 | Chromadex Inc | Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones. |
US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
US20220249535A1 (en) * | 2019-04-05 | 2022-08-11 | Rejuvenation Therapeutics | Compositions comprising nicotinamide adenine dinucleotide-related compounds and use thereof |
EP3980028A1 (en) * | 2019-06-05 | 2022-04-13 | Société des Produits Nestlé S.A. | Reduced nicotinamideribosides for treating/preventing skeletal muscle disease |
EP3980027A1 (en) * | 2019-06-05 | 2022-04-13 | Société des Produits Nestlé S.A. | Reduced nicotinamideribosides for the treatment/prevention of liver disease |
JP2022534869A (ja) * | 2019-06-05 | 2022-08-04 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 腎疾患を治療又は予防するための還元型ニコチンアミドリボシド |
US20200397807A1 (en) * | 2019-06-18 | 2020-12-24 | MitoPower, LLC | Nicotinyl riboside compounds and their uses |
US20220324899A1 (en) * | 2019-08-14 | 2022-10-13 | Metro International Biotech, Llc | Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide |
FR3103702B1 (fr) * | 2019-11-28 | 2022-02-11 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes |
CN110755432A (zh) * | 2019-12-02 | 2020-02-07 | 浙江大学 | 烟酰胺在制备治疗手足皮肤反应制剂中的应用 |
FR3107897B1 (fr) * | 2020-03-06 | 2023-05-26 | Nuvamid Sa | Dérivés de nicotinamide mononucléotides |
US20230133114A1 (en) * | 2020-03-09 | 2023-05-04 | Societe Des Produits Nestle S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of viral and bacterial infections |
EP4117677A1 (en) * | 2020-03-09 | 2023-01-18 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions |
WO2021180741A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions |
WO2021180732A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions |
FR3108032B1 (fr) * | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes |
FR3108031B1 (fr) * | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes |
CN111454311B (zh) | 2020-04-03 | 2021-10-19 | 深圳市迪克曼科技开发有限公司 | 烟酰胺核糖的有机酸盐及其组合物与制备方法 |
EP3901160A1 (en) * | 2020-04-25 | 2021-10-27 | Nuvamid SA | Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus |
EP4139322A1 (en) * | 2020-04-24 | 2023-03-01 | Nuvamid SA | Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus |
WO2021231874A1 (en) * | 2020-05-15 | 2021-11-18 | Psimos, Inc | Composition for growth stimulation and resistance to stress factors for plants of the cannabaceae family |
CN113768946A (zh) * | 2020-05-25 | 2021-12-10 | 南京帝昌医药科技有限公司 | 一种治疗糖尿病皮肤并发症的软膏及其制备方法 |
US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
US20230255994A1 (en) * | 2020-07-01 | 2023-08-17 | Metro International Biotech, Llc | Treatment of covid-19 and/or acute kidney injury |
CN114053292A (zh) * | 2020-07-31 | 2022-02-18 | 高志玲 | 烟酰胺核苷芳甲酸酯类化合物及其组合物的用途以及化合物晶型 |
JP2023538259A (ja) * | 2020-08-07 | 2023-09-07 | ヌバミッド エスエー | 抗悪性腫瘍薬誘発毒性の処置および防止におけるニコチンアミドモノヌクレオチド誘導体およびその使用 |
WO2022077276A1 (zh) * | 2020-10-14 | 2022-04-21 | 音芙医药科技(上海)有限公司 | 烟酰胺单核苷酸与发酵乳杆菌联合在制备缓解皮肤光老化制剂中的应用 |
CA3206030A1 (en) * | 2020-12-18 | 2022-06-23 | Nuvamid Sa | Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of a red blood cell disorder |
WO2022251491A1 (en) | 2021-05-27 | 2022-12-01 | Metro International Biotech, Llc | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
CN113308436A (zh) * | 2021-06-24 | 2021-08-27 | 海南赛奥干细胞生物科技有限公司 | 一种人类骨髓、脐带血干细胞处理试剂盒及干细胞分离方法 |
CN113398145B (zh) * | 2021-07-02 | 2022-10-14 | 合肥康诺生物制药有限公司 | 含nad与氨氯地平的药物组合物及其用途 |
KR20240047371A (ko) * | 2021-07-12 | 2024-04-12 | 싸이토키네틱스, 인코포레이티드 | Cd38 조절제 및 이의 사용 방법 |
CA3231499A1 (en) * | 2021-09-30 | 2023-04-06 | Bing Yan | Nicotinamide riboside trioleates chloride, compositions containing this compound, and methods of making and using this compound |
CN115304655A (zh) * | 2021-11-23 | 2022-11-08 | 中立安(北京)医药科技有限公司 | 烟酰胺单核苷类衍生物及其制备方法和应用 |
CN115232184A (zh) * | 2021-12-06 | 2022-10-25 | 宁波熙健医药科技有限公司 | 呋喃核糖基吡啶衍生物及其药物组合物和用途 |
CN115400140B (zh) * | 2022-01-27 | 2024-02-20 | 宁波熙健医药科技有限公司 | 呋喃核糖基吡啶衍生物用于预防或治疗癫痫或惊厥的用途 |
WO2023154844A2 (en) * | 2022-02-10 | 2023-08-17 | Workman David Henry | Compositions comprising nad+ and associated methods of treatment |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2798076A (en) | 1952-03-14 | 1957-07-02 | Hoffmann La Roche | 1-isonicotinyl-2-hydroxyalkylhydrazines |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
DE69721339T2 (de) | 1996-10-16 | 2004-01-22 | Ribapharm, Inc., Costa Mesa | Monozyklische l-nukleoside, analoga und ihre anwendungen |
US6337065B1 (en) | 1998-12-01 | 2002-01-08 | University Of Kentucky Research Foundation | Method for enhancing protective cellular responses to genotoxic stress in skin |
US6495537B1 (en) | 1998-12-01 | 2002-12-17 | University Of Kentucky Research Foundation | Method for inhibition of photocarcinogenesis or photoimmunosuppression using niacin |
US6288089B1 (en) | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
JP4156841B2 (ja) | 2000-04-14 | 2008-09-24 | ナイアダイン コーポレーション | ナイアシンの経皮送達用局所製剤および高脂血症の処置方法 |
US6689760B1 (en) | 2000-07-10 | 2004-02-10 | Enzrel Inc. | Anti-mycobacterial compositions |
CA2421269A1 (en) | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
WO2005002672A2 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
US8114626B2 (en) | 2004-02-10 | 2012-02-14 | Trustees Of Dartmouth College | Yeast strain and method for using the same to produce nicotinamide riboside |
US20050227327A1 (en) | 2004-02-10 | 2005-10-13 | Brenner Charles M | Nicotinamide riboside kinase compositions and methods for using the same |
WO2005077091A2 (en) | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
US7776326B2 (en) | 2004-06-04 | 2010-08-17 | Washington University | Methods and compositions for treating neuropathies |
US20060229265A1 (en) * | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
AU2006278396A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
EP3369738B1 (en) | 2005-11-18 | 2020-05-20 | Cornell Research Foundation, Inc. | Method for making nicotinoyl ribosides and nicotinamide beta-riboside |
US20120135091A1 (en) | 2007-01-18 | 2012-05-31 | Roth Mark B | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
CA2676609A1 (en) | 2007-01-26 | 2008-07-31 | Washington University | Methods and compositions for treating neuropathies |
TW200918542A (en) | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
JP5425891B2 (ja) | 2008-05-01 | 2014-02-26 | サートリス ファーマシューティカルズ, インコーポレイテッド | サーチュイン調節薬としてのキノリンおよび関連する類似体 |
EA020578B1 (ru) | 2008-07-03 | 2014-12-30 | Сертрис Фармасьютикалз, Инк. | Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина |
EP2364698A4 (en) | 2008-07-25 | 2011-09-14 | Snu R&Db Foundation | DAPSON AS A DERIVED COMPOSITION FOR CONTROLLING AGING AND / OR EXTENDING LIFE |
AU2009295946B2 (en) | 2008-09-29 | 2013-03-21 | Sirtris Pharmaceuticals, Inc. | Chromenone analogs as sirtuin modulators |
PE20120057A1 (es) | 2008-12-19 | 2012-02-24 | Sirtris Pharmaceuticals Inc | Compuestos de tiazolopiridina moduladores de sirtuina |
RU2550821C2 (ru) | 2009-10-29 | 2015-05-20 | Сертрис Фармасьютикалз, Инк. | Бициклические пиридины и аналоги в качестве модуляторов сиртуина |
US9603862B2 (en) | 2009-12-14 | 2017-03-28 | Cornell University | Activation and activators of SIRT5 |
WO2012094343A1 (en) | 2011-01-05 | 2012-07-12 | Trilink Biotechnologies | Chemically substituted thermosensitive probes and cofactors for hot start ligation |
WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
WO2012125900A1 (en) | 2011-03-16 | 2012-09-20 | Enanta Pharmaceuticals, Inc. | 2'-allene-substituted nucleoside derivatives |
WO2013044030A1 (en) | 2011-09-23 | 2013-03-28 | Enanta Pharmaceuticals, Inc. | 2'-chloroacetylenyl substituted nucleoside derivatives |
RU2014120180A (ru) | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные бициклические аза-гетероциклы и аналоги в качестве модуляторов сиртуина |
RU2014120168A (ru) | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные бициклические азагетероциклы и аналоги в качестве модуляторов сиртуина |
KR20140077963A (ko) | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
JP6289460B2 (ja) | 2012-07-16 | 2018-03-07 | コーネル ユニヴァーシティー | 難聴を治療するためのニコチンアミドリボシド |
GB201313465D0 (en) * | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
EP3063163B1 (en) | 2013-10-30 | 2022-08-10 | Chromadex Inc. | Nicotinamide riboside compositions for topical use in treating skin conditions |
-
2015
- 2015-06-05 WO PCT/IB2015/054281 patent/WO2015186114A1/en active Application Filing
- 2015-06-05 MX MX2016016071A patent/MX2016016071A/es unknown
- 2015-06-05 US US15/315,160 patent/US10485814B2/en active Active
- 2015-06-05 CN CN201580041352.4A patent/CN106715455A/zh active Pending
- 2015-06-05 KR KR1020177000145A patent/KR20170008320A/ko unknown
- 2015-06-05 BR BR112016028672A patent/BR112016028672A2/pt not_active Application Discontinuation
- 2015-06-05 EP EP15729244.2A patent/EP3152220A1/en not_active Withdrawn
- 2015-06-05 RU RU2016149767A patent/RU2016149767A/ru unknown
- 2015-06-05 CA CA2951287A patent/CA2951287A1/en not_active Abandoned
- 2015-06-05 JP JP2016571240A patent/JP6559713B2/ja not_active Expired - Fee Related
- 2015-06-05 AU AU2015270090A patent/AU2015270090A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2015186114A1 (en) | 2015-12-10 |
US20170189433A1 (en) | 2017-07-06 |
US10485814B2 (en) | 2019-11-26 |
JP6559713B2 (ja) | 2019-08-14 |
EP3152220A1 (en) | 2017-04-12 |
RU2016149767A (ru) | 2018-07-16 |
AU2015270090A1 (en) | 2016-12-22 |
JP2017516833A (ja) | 2017-06-22 |
KR20170008320A (ko) | 2017-01-23 |
BR112016028672A2 (pt) | 2017-08-22 |
CN106715455A (zh) | 2017-05-24 |
CA2951287A1 (en) | 2015-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016016071A (es) | Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos. | |
CU24183B1 (es) | Derivados de ácido 3-fenilpropiónico ramificados | |
BR112014029754A2 (pt) | soluções de tensoativos contendo n-metil-n-oleilglucaminas e n-metil-n-c12-c14-acilglucaminas | |
MX2016015997A (es) | Preparacion y uso de beta-d-nicotinamida ribosido cristalina. | |
GT201300208A (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos | |
BR112013020513A2 (pt) | adoçante stevia altamente solúvel | |
PE20130396A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma | |
CR20140312A (es) | 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
NZ743706A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
MY189483A (en) | Purinone derivative | |
UY33758A (es) | Acidos indaniloxidihidrobenzofuranilaceticos | |
WO2014004861A3 (en) | Methods of treating pediatric metabolic syndrome | |
CO7350620A2 (es) | Nuevos derivados de piridina | |
CO6761400A2 (es) | Combinación de análogos de glucagón acilados con análogos de insulina | |
PE20142359A1 (es) | Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas | |
BR112014029781A2 (pt) | soluções de tensoativos contendo n-metil-n-c8-c10-acilglucaminas e n-metil-n-c12-c14-acilglucaminas | |
UY32240A (es) | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. | |
UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
UY33509A (es) | Metodos y composiciones para el tratamiento de la alergia | |
MX2021008738A (es) | Regimenes de dosificacion de melflufen para cancer. | |
IN2014DN08582A (es) | ||
AR086647A1 (es) | Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k | |
MX348979B (es) | Agente de control de enfermedades de las plantas. | |
MX370884B (es) | Derivados de catecolamina enriquecidos con deuterio asimétrico posición-específico y medicamentos que comprenden los compuestos. | |
BR112014030992A2 (pt) | composições compreendendo calcogenetos e métodos relacionados |